Eli Lilly's oral weight-loss pill shows promise

Eli Lilly's experimental oral weight-loss drug showed less effectiveness than expected in trials, causing its shares to drop. However, the drug still has significant potential to make obesity treatment more accessible to a wider population.

Eli Lilly is making progress on a new weight loss pill that uses the same GLP-1 technology as its popular injections. While the pill version doesn’t work as well for weight loss as the shots, it could still be a game-changer for patients who prefer oral medication. The company plans to seek FDA approval by year-end, with hopes of hitting the market by 2026.

A new study shows that Eli Lilly's experimental weight-loss pill helped participants lose up to 12% of their body weight, potentially paving the way for its market release next year. This pill could offer an alternative to weight-loss injections, though the company's stock dropped by over 10% despite the promising results.

A new daily weight loss pill has shown promising results in trials, with participants losing an average of 12% of their body weight over 72 weeks. This could be a game-changer for people struggling with obesity.

A new pill developed by Eli Lilly has shown significant weight loss results in clinical trials, marking a potential breakthrough in obesity treatment. The drug's success could offer a simpler alternative to existing weight-loss medications, which often require injections.